Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback